Objective: Lung cancer remains the leading cause of cancer deaths worldwide. The surgical approach to locally advanced non-small cell lung cancer (NSCLC) goes beyond the classical approach and requires a multidisciplinary approach both preoperatively and postoperatively. In addition to the tumor size, the location of T3 tumors affects the extent of the surgery. Materials and Methods: Patients who underwent lung resection for cancer between March 2019 and October 2022 were retrospectively reviewed. Patients who underwent chest wall resection were evaluated in terms of age, gender, pathology, type of operation, survival, recurrence, complications, receipt of preoperative chemotherapy, tumor node metastasis (TNM) stage, whether or not mediastinoscopy was performed, STAS (The spread through air spaces) positivity, visceral pleural invasion, parietal pleural invasion, lymphovascular invasion, perineural invasion, and alveolar/bronchial wall invasion. Results: Thoracic wall resection was performed in nine patients with locally advanced NSCLC. The use of prolene mesh was required in eight patients. All patients complained of pain in the thoracic wall in the preoperative period. Postoperative pathology results showed STAS positivity in four patients; alveolar/bronchial wall invasion in four; and visceral, parietal, pleural, and lymphovascular invasion in seven. The mean survival of the patients was 24.20 months (0.63–39). No patient developed recurrence during the follow-up period. Conclusion: Chest wall resection and reconstruction for lung cancer is a surgical treatment method that should be performed without violating respiratory physiology and by using a small amount/number of synthetic materials.
Objective: During the pandemic, elective cases other than those requiring emergency thoracic surgery were postponed. Depending on the magnitude of the impact the pandemic posed on hospitals and clinics, there have been changes in the number and variety of cases of thoracic surgery. The intention behind conducting this study was to share the experiences gained by a thoracic surgery clinic during the pandemic period.Methods: Altogether, 214 patients were included in the study. Patient data that were recorded included those on age, gender, lung pathology, duration of hospital stay, positivity for COVID-19, survival, and causes of death.Results: Of the 214 patients operated on, 12 died during the postoperative period. Eight of these patients died due to their primary disease and one died due to gastrointestinal bleeding, whereas the remaining three patients died due to COVID-19 infection.Conclusions: If opportunities and facilities favorable for the administration of surgical treatment are made available, surgical treatment services can be offered safely to all patients
During the COVID-19 pandemic, all elective surgeries, except emergency surgeries and surgeries for patients with malignancy, were postponed. In this study, patients who presented to the thoracic surgery clinic of our hospital during and those who presented before the COVID-19 pandemic were compared, and changes in characteristics of the patients presenting to the thoracic surgery clinic during the COVID-19 pandemic were investigated.Material and Method: Age, gender, and reason for admission to the hospital were documented for all patients who presented to the thoracic surgery clinic of our hospital during March 2019-March 2020 and March 2020-March 2021. Patients presenting to the clinic were categorized into malignancy, trauma, chest pain, pneumothorax, and other disease groups.Results: In total, 947 patients presented to the clinic in the prepandemic period. Conversely, 756 patients presented to the clinic during the pandemic. In the pre-pandemic period, 353 patients presented with trauma; this number decreased to 154 during the pandemic. Additionally, during the pandemic, a decrease was observed in all patient admissions other than those due to malignancies. Conclusion:During the pandemic, there has been a decrease in patient admissions due to trauma, mostly as a result of curfews and restrictions. However, there has been a significant increase in the number of patients presenting with lung malignancies during the pandemic. This may be due to findings of incidental lung masses in the thoracic computed tomography performed after COVID-19 prediagnosis.
Amaç: Plevral aralıkta serbest hava görülmesi olarak tanımlanan pnömotoraksın sekonder sebepleri arasında en sık görülen patoloji Kronik obstruktif akciğer hastalığı (KOAH)’dır. KOAH’lı hastalarda sınırlı pulmoner rezerv nedeniyle pnömotoraks tedavisinin hızlı ve etkin olması önemlidir. Bu çalışmanın amacı, KOAH hastalarında gelişen pnömotoraksta otolog kan ile yapılan plörödezis işleminin sonuçlarını incelemektir. Gereç ve Yöntem: Kliniğimizde şubat 2017-şubat 2020 yılları arasında KOAH hastalığı olan ve pnömotoraks sebebiyle tüp torakostomi uygulanan ve otolog kan ile plöredezis işlemi yapılan olgular incelendi. Yaş, cinsiyet, sigara öyküsü, plöredezis sonrası semptomlar, nüks oranları, komplikasyon ve hastanede yatış süreleri açısından retrospektif olarak değerlendirildi. Bulgular: Yaş ortalaması 65,5 (54-76) olan 27 olgunun tamamı sigara içen erkek hastalardan oluşmaktaydı. Olguların hava kaçağı ortalama süresi 9 (5-16) gün, ortalama yatış süresi 12 gün (8-19), 3 aylık takiplerindeki nüks oranı ise %11.1 olarak (3 olgu) bulundu. Olguların hiçbirinde plöredezis sonrası allerjik reaksiyon, enfeksiyon ve ağrı gözlenmedi. 1 olguda (%3,7) işlem sonrası cilt altı amfizemi, 5 olguda (%18,5) dispne gelişti. Olgularda yaş arttıkça işlem sonrası saturasyon düşüklüğünün anlamlı olarak arttığı izlendi. Saturasyon değerinin artmasının dispne şikayetini anlamlı şekilde azalttığı, yüksek saturasyon değerlerinin 3 aylık periyotta nüks oranını anlamlı şekilde azalttığı gözlenmektedir (p
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.